MetLife Inc (MET) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently trading in pre-market with a slight positive movement, but the financial performance shows declining net income and EPS, which raises concerns. Additionally, hedge funds are aggressively selling, and there are no recent positive news catalysts or significant insider activity to support a bullish case. While options data shows a slightly bullish sentiment in volume, the high Open Interest Put-Call Ratio indicates caution. Analyst ratings are mixed with lowered price targets, reflecting challenges in the life insurance sector. Given the user's impatience and unwillingness to wait for optimal entry points, it is better to hold off on investing in MET at this time.
The MACD is positive at 0.937, showing bullish momentum, but it is contracting. RSI is at 78.514, indicating a neutral zone. Moving averages are converging, suggesting indecision in the market. Key resistance levels are at 77.235 and 79.271, while support levels are at 73.938 and 70.641. The stock is trading near its resistance levels, which may limit further upside in the short term.

No significant positive catalysts. The stock shows a 60% chance of gaining 4.15% in the next week based on historical patterns.
Hedge funds are aggressively selling, with a 119940.49% increase in selling activity over the last quarter. Declining net income and EPS in the latest quarter. Analysts have lowered price targets, reflecting challenges in the life insurance sector.
In Q4 2025, revenue increased by 26.69% YoY to $23.67 billion. However, net income dropped by 37.21% YoY to $778 million, and EPS fell by 34.27% YoY to 1.17. Gross margin remained unchanged.
Analyst ratings are mixed. Several firms have lowered price targets, citing challenges in the life insurance sector, including premium growth concerns and economic uncertainty. The average price target is around $93, which suggests potential upside, but the sentiment is cautious overall.